Danaher Corporation (NYSE:DHR) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
A number of other research firms have also recently weighed in on DHR. Janney Montgomery Scott cut shares of Danaher Corporation from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 7th. Deutsche Bank AG reissued a “buy” rating and issued a $97.00 price objective on shares of Danaher Corporation in a research report on Wednesday, June 21st. Zacks Investment Research raised shares of Danaher Corporation from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a research report on Tuesday, April 4th. Credit Suisse Group reissued a “buy” rating and issued a $93.00 price objective on shares of Danaher Corporation in a research report on Wednesday, May 24th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $88.00 price objective (down from $89.00) on shares of Danaher Corporation in a research report on Friday, April 21st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $92.26.
Danaher Corporation (DHR) traded up 0.17% on Friday, reaching $83.07. The company had a trading volume of 2,877,291 shares. Danaher Corporation has a 52-week low of $75.71 and a 52-week high of $88.01. The firm has a market capitalization of $57.66 billion, a price-to-earnings ratio of 25.32 and a beta of 1.05. The stock’s 50-day moving average price is $84.47 and its 200 day moving average price is $83.63.
Danaher Corporation (NYSE:DHR) last announced its quarterly earnings results on Thursday, April 20th. The conglomerate reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.01. Danaher Corporation had a return on equity of 11.82% and a net margin of 12.30%. The firm had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.17 billion. During the same period in the prior year, the firm earned $1.08 EPS. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, equities analysts anticipate that Danaher Corporation will post $3.92 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 30th will be paid a dividend of $0.14 per share. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.67%. Danaher Corporation’s dividend payout ratio is presently 17.02%.
TRADEMARK VIOLATION WARNING: “Danaher Corporation (NYSE:DHR) Cut to Sell at BidaskClub” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/08/danaher-corporation-nysedhr-cut-to-sell-at-bidaskclub.html.
In related news, EVP William K. Daniel sold 17,444 shares of the firm’s stock in a transaction that occurred on Tuesday, April 25th. The shares were sold at an average price of $83.07, for a total transaction of $1,449,073.08. Following the transaction, the executive vice president now owns 132,995 shares in the company, valued at $11,047,894.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Angela S. Lalor sold 10,815 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $84.16, for a total transaction of $910,190.40. Following the transaction, the senior vice president now owns 39,020 shares in the company, valued at approximately $3,283,923.20. The disclosure for this sale can be found here. Insiders have sold 82,265 shares of company stock worth $6,815,839 in the last quarter. Company insiders own 12.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of DHR. Lee Danner & Bass Inc. raised its position in Danaher Corporation by 0.4% in the first quarter. Lee Danner & Bass Inc. now owns 2,635 shares of the conglomerate’s stock worth $225,000 after buying an additional 10 shares in the last quarter. Rehmann Capital Advisory Group raised its position in Danaher Corporation by 0.6% in the first quarter. Rehmann Capital Advisory Group now owns 2,959 shares of the conglomerate’s stock worth $253,000 after buying an additional 19 shares in the last quarter. Alpha Windward LLC raised its position in Danaher Corporation by 0.8% in the first quarter. Alpha Windward LLC now owns 2,605 shares of the conglomerate’s stock worth $223,000 after buying an additional 21 shares in the last quarter. Guardian Life Insurance Co. of America raised its position in Danaher Corporation by 1.0% in the first quarter. Guardian Life Insurance Co. of America now owns 2,356 shares of the conglomerate’s stock worth $202,000 after buying an additional 24 shares in the last quarter. Finally, Assetmark Inc. raised its position in Danaher Corporation by 0.5% in the first quarter. Assetmark Inc. now owns 6,622 shares of the conglomerate’s stock worth $566,000 after buying an additional 30 shares in the last quarter. Institutional investors and hedge funds own 76.32% of the company’s stock.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.